1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Evogene Ltd.

Evogene Ltd.

EVGN.TA
Evogene Ltd.IL flagTel Aviv Stock Exchange
134.50
ILA
+6.30
- -
11.59MMarket Cap
Evogene Ltd.
EVGN.TA
(Tel Aviv Stock Exchange)

Recent

price

134.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.51
9.27
8.91
5.79
4.4
2.57
1.31
0.68
0.29
0.37
0.23
0.41
0.65
0.98
- -
0.18
Revenue per Share
0.37
-1.37
-4.5
-5.8
-6.8
-7.7
-8.1
-8.06
-7.03
-8.3
-6.87
-6.46
-5.23
-2.89
- -
-0.72
Basic EPS, GAAP
-0.93
-2.63
-3.49
-4.97
-5.69
-4.91
-6.42
-6.03
-7.21
-7.17
-6.32
-6.03
-4.85
-3.57
- -
-1.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-19.48
-22.67
-23.65
-30.21
-37.75
-45.44
-53.45
-60.48
-63.6
-51.15
-56.65
-56.32
-48.04
- -
-35
Book Value per Share
- -
26.15
63.21
46.34
40.99
34.31
26.97
19.53
16.75
14.47
11.92
5.01
3.4
0.46
- -
0.97
Tangible Book Value per Share
2
2
2
3
3
3
3
3
3
3
4
4
5
6
- -
8
Basic Weighted Avg Shares
15
17
18
15
11
7
3
2
1
1
1
2
3
6
4
2
Sales/Revenue/Turnover
-21.36
-18.31
-49.6
-105.13
-161.03
-322.46
-649.13
-1,144.19
-2,810.89
-2,385.96
-3,328.28
-1,608.42
-744.63
-336.33
-364.24
-728.94
Operating Margin (%)
1
2
2
2
2
2
2
2
3
3
2
3
1
1
1
1
Depreciation Expense
1
-3
-9
-15
-17
-20
-21
-21
-18
-23
-28
-27
-24
-16
-8
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.33
-14.77
-50.5
-100.13
-154.67
-299.57
-616.33
-1,188.21
-2,405.31
-2,247.5
-2,988.49
-1,590.33
-800.77
-295.59
-220.22
-390.53
Profit Margin (%)
- -
48
121
110
99
84
68
50
43
42
50
32
28
3
12
10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
11
11
2
1
1
LT Debt
- -
48
125
116
104
87
69
50
60
57
63
35
29
15
12
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
10
Market Capitalization
881
742
653

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
21
16
15
Cash, Cash Equivalents & STI
16
13
13
Accounts Receivable, Net
- -
- -
- -
Inventories
2
- -
- -
Total Current Liabilities
4
3
5
Payables & Accruals
2
2
3
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.85%
-23.75%
-19.3%
Free Cash Flow
1.3%
-5.65%
-32.91%
Net Income, GAAP
-3.9%
-15.02%
-48.53%
Sales/Revenue/Turnover
4.7%
40.73%
-30.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
1
2
2
6
2025
2
1
- -
- -
4
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.76
-1.06
-1.31
0.06
-2.89
2025
-0.38
-0.62
0.44
-0.61
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
EOM Pharmaceuticals Holdings, Inc. (IMUC)
Wuhan YZY Biopharma Co Ltd (2496.HK)
Alector, Inc. (ALEC)
Carna Biosciences, Inc. (4572.T)
Medicus Pharma Ltd. (MDCXW)
Lyra Therapeutics, Inc. (LYRA)
Business
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN.TA) Evogene Ltd. is an Israel-based computational biology company founded in 1999 and headquartered in Rehovot that leverages its Computational Predictive Biology (CPB) platform and three proprietary AI-driven technological engines—MicroBoost AI for microbe-based products, ChemPass AI for small molecule-based products, and GeneRator AI for genetic element-based products—to accelerate discovery and development of life-science products in agriculture, human health, and industrial applications; core offerings include improved seed traits such as enhanced yield, disease resistance, and stress tolerance in crops like corn, soybean, and wheat; microbial-based biologicals for insect control, disease management, and plant growth promotion; ag-chemical solutions; human microbiome-based therapeutics; and industrial castor bean seeds for biofuel and biopolymer production. The company operates globally through subsidiaries including Biomica Ltd. for microbiome therapeutics targeting immuno-oncology and metabolic diseases, AgPlenus Ltd. for crop protection chemicals, and Casterra Ag Ltd. for castor cultivation, serving pharmaceutical firms, agribusinesses, farmers, and industrial manufacturers primarily in North America, Europe, Israel, and emerging markets. Evogene generates revenue through research collaborations, licensing agreements, royalties, product sales, and grants. In 2025, Evogene completed the sale of most Lavie Bio Ltd.'s ag-biologicals assets and its MicroBoost AI for Agriculture platform to ICL Group Ltd. for $18.71 million in July, strengthening its cash position to support an 18-month runway; launched ChemPass AI version 1.0 in partnership with Google Cloud, trained on 38 billion molecular structures to enhance small molecule design for pharmaceuticals and crop protection; integrated AgPlenus operations into the parent company while maintaining partnerships with Bayer and Corteva; initiated a collaboration with Professor Ehud Gazit for small molecule therapeutics targeting gout and PKU; reduced workforce by 30% at the parent level and 40% at AgPlenus as part of a broader restructuring to cut operating expenses by 31% year-over-year to $7.7 million in H1 2025; and raised $4.4 million via an at-the-market equity offering.